Company intelligence / Profile preview

Proprius Pharmaceuticals

San Diego, California, United Statesreuters.com ↗

Ownership: Private
Development stage: Other

Overview

Proprius Pharmaceuticals developed personalized medicine solutions focused on rheumatology and autoimmune diseases. Its lead asset, Indaflex™ (topical indomethacin cream), reached Phase II trials for osteoarthritis of the knee. Another candidate, PRO‑515, targeted rheumatoid arthritis but was discontinued. The company combined proprietary therapeutics with diagnostic services to differentiate its approach. In February 2008 it was acquired by Cypress Bioscience and ceased independent operations thereafter.

Therapeutic areas: ImmunologyRheumatology
Modalities: Small moleculeTopical drug formulationBiologicMedical deviceVaccine
Industry: Biotech

Beyond the preview

Go deeper on Proprius Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proprius Pharmaceuticals.

Explore the full profile